Submit Your Article CMED MEACR meeting
An official publication of the Middle-Eastern Association for Cancer Research
Clinical Cancer Investigation Journal
ARTICLE
Year: 2013   |   Volume: 2   |   Issue: 4   |   Page: 294-297     View issue

Bisphosphonates and innovative drugs in the prevention of skeletal complications secondary to metastatic prostate cancer


Nabil Ismaili, Ali Tahri, Rhizlane Belbaraka
Abstract

Over than 80% of patients with locally advanced prostate cancer will develop bone metastases during the disease management. These metastases are often responsible for complications that impaired the quality of life, impaired the prognosis and increased the mortality by prostate cancer (PC). Two drugs are currently approved by the scientific community in the prevention of skeletal complications secondary to castration-resistant prostate cancer metastatic to bone (CRPCMB), zoledronic acid at a dose of 4 mg intravenously every 3-4 weeks and denosumab at a dose of 120 mg subcutaneously every 4 weeks. This aim of the preset paper was to review the current literature on the mechanism of action, efficacy, and safety profile of these two classes of molecules in the management of CRPCMB.

Cite this article
Vancouver
Ismaili N, Tahri A, Belbaraka R. Bisphosphonates and innovative drugs in the prevention of skeletal complications secondary to metastatic prostate cancer. Clin Cancer Investig J. 2013;2(4):294-7. https://doi.org/10.4103/2278-0513.121517
APA
Ismaili, N., Tahri, A., & Belbaraka, R. (2013). Bisphosphonates and innovative drugs in the prevention of skeletal complications secondary to metastatic prostate cancer. Clinical Cancer Investigation Journal, 2(4), 294-297. https://doi.org/10.4103/2278-0513.121517

Sitemap | What's New | Feedback | Copyright and Disclaimer | Privacy Notice
© Clinical Cancer Investigation Journal | Published by Polaris Publication
Online since 01 December, 2011
Editorial and Ethics Policies
Creative Commons  Open Access Journal View mobile site 
ISSN: Print -2278-1668, Online - 2278-0513